Antidepressant use in pregnancy: new concerns, old dilemmas

References

• Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA289, 3095–3105 (2003).
   PubMed Web of Science ®Google Scholar
• Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am. J. Psychiatry151, 979–986 (1994).
   PubMed Web of Science ®Google Scholar
• Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br. J. Psychiatry150, 662–673 (1987).
   PubMed Web of Science ®Google Scholar
• Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. New parents and mental disorders: a population-based register study. JAMA296, 2582–2589 (2006).
   PubMed Web of Science ®Google Scholar
• Mitchell AA. Systematic identification of drugs that cause birth defects – a new opportunity. N. Engl. J. Med.349, 2556–2559 (2003).
   PubMed Web of Science ®Google Scholar
• Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet. Gynecol.100, 465–473 (2002).
   PubMed Web of Science ®Google Scholar
• Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med.335, 1010–1015 (1996).
   PubMed Web of Science ®Google Scholar
• Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA279, 609–610 (1998).
   PubMed Web of Science ®Google Scholar
• Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res. Part A Clin. Mol. Teratol.79(4), 301–308 (2007).
   PubMed Web of Science ®Google Scholar
• Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res. B Dev. Reprod. Toxicol.80(1), 18–27 (2007).
   PubMed Web of Science ®Google Scholar
• Wogelius P, Norgaard M, Gislum M et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology17, 701–704 (2006).
   PubMed Web of Science ®Google Scholar
• Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet. Gynecol.106, 1289–1296 (2005).
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry63, 898–906 (2006).
   PubMed Web of Science ®Google Scholar
• Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry159, 2055–2061 (2002).
   PubMed Web of Science ®Google Scholar
• Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA293, 2372–2383 (2005).
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med.354, 579–587 (2006).
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart D et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med.336, 258–262 (1997).
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart DE et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry159, 1889–1895 (2002).
   PubMed Web of Science ®Google Scholar
• Misri S, Reebye P, Kendrick K et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am. J. Psychiatry163, 1026–1032 (2006).
   PubMed Web of Science ®Google Scholar
• Murray L. The impact of postnatal depression on infant development. J. Child Psychol. Psychiatry33, 543–561 (1992).
   PubMed Web of Science ®Google Scholar
• Casper RC, Fleisher BE, Lee-Ancajas JC et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drug during pregnancy. J. Pediatr.142, 402–408 (2003).
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics115, 411–425 (2005).
   PubMed Web of Science ®Google Scholar
• Bonari L, Pinto N, Ahn C, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can. J. Psychiatry49, 726–735 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA295, 499–507 (2006).
   PubMed Web of Science ®Google Scholar
• Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch. Womens Ment. Health8, 214–220 (2005).
   PubMed Web of Science ®Google Scholar
• Honein MA, Moore CA, Lyon Daniel K, Erickson JD. Problems with informing women adequately about teratogen risk: some barriers to preventing exposures to known teratogens. Teratology65(5), 202–204 (2002).
   PubMedGoogle Scholar
• Wisner K, Zarin D, Holmboe E et al. Risk-benefit decision making for treatment of depression during pregnancy. Am. J. Psychiatry157, 1933–1940 (2000).
   PubMed Web of Science ®Google Scholar